1. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Issue 7 (July 2021) Authors: Howard, James F; Bril, Vera; Vu, Tuan; Karam, Chafic; Peric, Stojan; Margania, Temur; Murai, Hiroyuki; Bilinska, Malgorzata; Shakarishvili, Roman; Smilowski, Marek; Guglietta, Antonio; Ulrichts, Peter; Vangeneugden, Tony; Utsugisawa, Kimiaki; Verschuuren, Jan; Mantegazza, Renato; De Bleeker, Jan;... Journal: Lancet neurology Issue: Volume 20:Issue 7(2021) Page Start: 526 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗